-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, JV6Br07zgnRjijIGgaLQPVStS4YDo++DW1zGb4SXG9ALLA9zR+9nZeuToMrk0EX3 bfo7b/J/H3Fm3whIDdCYHQ== 0000947871-03-000950.txt : 20030404 0000947871-03-000950.hdr.sgml : 20030404 20030404164600 ACCESSION NUMBER: 0000947871-03-000950 CONFORMED SUBMISSION TYPE: 424B3 PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20030404 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MERRILL LYNCH PIERCE FENNER & SMITH INC CENTRAL INDEX KEY: 0000728612 STANDARD INDUSTRIAL CLASSIFICATION: SECURITY BROKERS, DEALERS & FLOTATION COMPANIES [6211] STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 424B3 SEC ACT: 1933 Act SEC FILE NUMBER: 333-92161 FILM NUMBER: 03640321 BUSINESS ADDRESS: STREET 1: 4 WORLD FINANCIAL CENTER STREET 2: NORTH TOWER FL 12 CITY: NEW YORK STATE: NY ZIP: 10080 BUSINESS PHONE: 2124496202 MAIL ADDRESS: STREET 1: 4 WORLD FINANCIAL CENTER STREET 2: NORTH TOWER FL 12 CITY: NEW YORK STATE: NY ZIP: 10080 424B3 1 f424b3_040203-pharhold.txt FORM 424(B)(3) FOR PHARMACEUTICAL HOLDRS FILED PURSUANT TO RULE NO. 424(b)(3) PROSPECTUS SUPPLEMENT REGISTRATION NO. 333-92161 (To Prospectus dated March 12, 2002) 333-95805 [LOGO OMITTED] 1,000,000,000 Depositary Receipts Pharmaceutical HOLDRS (SM) Trust This prospectus supplement supplements information contained in the prospectus dated March 12, 2002 relating to the sale of up to 1,000,000,000 depositary receipts by the Pharmaceutical HOLDRS (SM) Trust. The share amounts specified in the table on page 12 of the base prospectus shall be replaced with the following: Primary Share Trading Name of Company Ticker Amounts Market ---------------------------------------------------- --------- --------- ------- Abbott Laboratories ABT 14 NYSE Allergan, Inc. AGN 1 NYSE Andrx Corporation-Andrx Group ADRX 2 NASDAQ Advanced Medical Optics, Inc. AVO 0.222222 NYSE Biovail Corporation BVF 4 NYSE Bristol-Myers Squibb Company BMY 18 NYSE Eli Lilly & Company LLY 10 NYSE Forest Laboratories, Inc. (1) FRX 4 NYSE ICN Pharmaceuticals, Inc. ICN 1 NYSE IVAX Corporation IVX 1.875 AMEX Johnson & Johnson JNJ 26 NYSE King Pharmaceuticals, Inc. KG 4.25 NYSE Merck & Co., Inc. MRK 22 NYSE Mylan Laboratories, Inc. (2) MYL 1.5 NYSE Pfizer Inc. PFE 58 NYSE Schering-Plough Corporation SGP 14 NYSE Watson Pharmaceuticals, Inc. WPI 1 NYSE Wyeth WYE 12 NYSE Zimmer Holdings, Inc. ZMH 1.8 NYSE
- --------------------------------------------------------- (1) Forest Laboratories, Inc. announced a two-for-one stock split on its common stock payable to shareholders of record on December 23, 2002. Forest Laboratories, Inc. began trading on a split-adjusted basis on January 9, 2003. As of January 14, 2003, the share amount of Forest Laboratories, Inc. represented by a round lot of 100 Pharmaceutical HOLDRS increased to 4 from 2. (2) Mylan Laboratories, Inc. announced a three-for-two stock split on its common stock payable to shareholders of record on January 17, 2003. Mylan Laboratories, Inc. began trading on a split-adjusted basis on January 28, 2003. As of January 31, 2003, the share amount of Mylan Laboratories, Inc. represented by a round lot of 100 Pharmaceutical HOLDRS increased to 1.5 from 1. The share amounts listed in the table above reflect all previous stock splits, dividends and business combination transactions. The date of this prospectus supplement is March 31, 2003. -----END PRIVACY-ENHANCED MESSAGE-----